They have almost $5/share of liquid net assets you idiot... negative results were expected. PLEASE, PLEASE, PLEASE SELL SHORT AT $1.80/SHARE!
Strike that, no public news. News is imminent. Check out the volume and closing in on a 52 week high. Do your own DD, but huge potential here trading just above net cash.
Risk of fine already factored in:
"QCOR reported 3Q13 Acthar sales of $227mn handily beating our Street-high
estimate of $195mn owing to particular strength in rheumatology and MS flares. Our
model revisions increased our 2014 sales to $1bn (prev. $900mn), which we do not
see as a stretch given 3Q annualized sales of $900mn. While we expect continued
robust Acthar growth in labeled indications (see below), we note increased risk from
the announcement of the SEC and NY US Attorney’s office involvement in the
ongoing USAO investigation. Our DCF analysis increased by $7/share, but we also
increased the value for a potential fine of $600mn (prev $400mn), resulting in a PO
increase of $4 to $84. The prospect of 2014 sales of $1bn could attract the
development of a generic Acthar formulation, which remains a long-term risk."
Sentiment: Strong Buy
Sooooo, basically, if you think NEUVAX is a scam and FBP will never come to fruition, the company is worth no more than $1.69 per share?
Perfect roundtrip trade... but I don't think I'll step off the platform for the next leg of the journey.
I don't invest. I trade. Successful trade becoming more successful as the price begins to melt.
People want the source regarding Herceptin, try looking at the study results. Yahoo won't let me post the link. Go to the NeuVax entry on Wikipedia, results are the 4th footnote.
Excerpt regarding chemo and Herceptin aka trastuzumab (found in the Dosing and Effect on DFS section at the above link):
Patients receiving the optimal dose of vaccine were more likely to have received chemotherapy in the adjuvant setting (89.2% vs 71.1% for controls; P = .03), a finding attributable to the finding that vaccinated patients were more likely to have lymph node-positive disease (70.3% vs 56.6% for controls; P = .22). In addition, because patients receiving the optimal dose were enrolled later in the trial after trastuzumab had become standard of care therapy for HER2+ breast cancer in the adjuvant setting, optimally dosed patients were more likely to have received trastuzumab (24.3%) than were controls (2.7%).